The three-dimensional perspective of CAR-T cell therapy in autoimmune diseases.

Jiayi Shen, Jianhua Mao, Qing Ye

Abstract readReview

In one paragraph

Review in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jiayi ShenDepartment of Nephrology, Children's Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310052, China.

Jianhua MaoDepartment of Nephrology, Children's Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310052, China; Department of Nephrology, First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, 310003, China. Electronic address: maojh88@zju.edu.cn.

Qing YeDepartment of Laboratory Medicine, Children's Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310052, China. Electronic address: qingye@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in haematological malignancies, ushering in the era of adoptive cell therapy. In recent years, CAR-T cell therapy has been progressively explored in autoimmune diseases (AIDs), with the goal of inducing deep immune remodelling and durable drug-free remission in selected patients. This review evaluates CAR-T cell therapy in AIDs through three clinically relevant dimensions: depth, breadth, and length. We use this framework to discuss therapeutic efficacy, immune remodelling mechanisms, disease spectra, target selection, long-term persistence and safety, with the aim of supporting more precise and controllable clinical development.

Indexed as

Autoimmune DiseasesImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsHumansReceptors, Antigen, T-CellTreatment OutcomeReceptors, Antigen, T-CellReceptors, Chimeric AntigenAutoimmune diseasesCAR-T cell therapyImmune remodellingPrecision therapyTargeted therapy

Identifiers

PMID42335674

DOI10.1016/j.ebiom.2026.106341

PMCPMC13316656

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.